# NM_006302.3(MOGS):c.2055T>C (p.Tyr685=)

https://sugi.bio/variant/mogs-p-tyr685

## Summary

**MOGS p.Tyr685= (c.2055T>C)** is classified **Conflicting classifications of pathogenicity** in MOGS (ClinVar, Conflicting submitters, 6 submitters; last evaluated 2026-06-01). Rare (popmax 0.197%, nfe); Associated with MOGS-congenital disorder of glycosylation.

**At a glance:** Conflicting classifications of pathogenicity · review: Conflicting submitters · rsID rs202094225 · 6 submitters · 1 linked condition · rare (popmax 0.197%, nfe)

## For patients & families {#patients}

This is a change in the MOGS gene that is of uncertain or conflicting significance (submitters disagree on it), submitted by 6 submitters, and is linked to MOGS-congenital disorder of glycosylation.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Typical inheritance (of this condition) | Autosomal recessive |
| Age of onset (of this condition) | Infancy, Neonatal |
| Diagnostic panels | MOGS is a diagnostic-grade gene on 14 Genomics England panels |

**Commonly reported features of MOGS-CDG** (across patients with this condition; presentation varies — frequencies from Orphanet):

- Retrognathia — Frequent (79-30%)
- Wide nose — Frequent (79-30%)
- Long eyelashes — Frequent (79-30%)
- Hirsutism — Frequent (79-30%)
- Seizure — Frequent (79-30%)
- Abnormal facial shape — Frequent (79-30%)
- Decreased circulating IgA level — Frequent (79-30%)
- Decreased circulating total IgM — Frequent (79-30%)

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0010767/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [MOGS](https://sugi.bio/atlas/gene/MOGS/) |
| Protein change (HGVS p.) | p.Tyr685= |
| Coding change (HGVS c.) | c.2055T>C |
| MANE Select transcript | [NM_006302](https://www.ncbi.nlm.nih.gov/nuccore/NM_006302) |
| dbSNP | [rs202094225](https://www.ncbi.nlm.nih.gov/snp/rs202094225/) |
| Variant type | single nucleotide variant |
| Location | chr2:74461734-74461734 (GRCh38) |
| ClinVar | [VCV281500](https://www.ncbi.nlm.nih.gov/clinvar/variation/281500/) |

**All HGVS expressions:** `LRG_1226:g.8677T>C`, `LRG_1226t1:c.2055T>C`, `NC_000002.11:g.74688861A>G`, `NC_000002.12:g.74461734A>G`, `NG_008922.1:g.8677T>C`, `NM_001146158.2:c.1737T>C`, `NM_006302.3:c.2055T>C`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP 0.156, GERP 0.704, phastCons 0.085 — weakly conserved position
- CADD: **PHRED 1.025**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **no splice effect predicted**. SpliceAI outputs four numbers per variant, not one: acceptor loss, donor loss, acceptor gain, donor gain (DS_AL / DS_DL / DS_AG / DS_DG). A loss score is an existing splice site weakened or destroyed; a gain score is a new site created or an existing one strengthened. The release publishes its own filter rule, which we read from the dataset rather than assume: an allele is reported only if the largest of its four deltas reaches 0.2. No allele at this position is in the release, so all four are under 0.2 for every alternate allele here. No figure is shown because none was read: the bound is deduced from that absence. It is a result, not a gap in our data, because the release scores every possible substitution across the transcripts it covers (Ensembl MANE v1.4) before it filters, so what survives for a gene is one continuous stretch. What is measured is that this position sits inside the stretch covered for MOGS (262 scored positions, the nearest 38 bases away); what is taken from the release's own description, rather than measured, is that coverage inside that stretch is continuous. On that, SpliceAI did score it. *ClinGen's SVI treats the largest of the four as evidence against a splicing effect at or below 0.1, where it may support BP4, and as uninformative between 0.1 and 0.2. We cannot tell which applies here, so these SpliceAI data support neither BP4 nor PP3; that is a statement about this evidence alone, not about the variant's other evidence.*
- Population frequency (gnomAD v4.1): grpmax **0.197%** (nfe) · FAF95 0.19% · FAF99 0.188% · 2,326/1,180,032 in the highest group · 2,557/1,614,188 alleles overall — rare (popmax 0.197%, nfe).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| European (non-Finnish) (grpmax) | 0.197% | 507 |
| Remaining individuals (not grpmax-eligible) | 0.173% | 579 |
| Admixed American | 0.152% | 660 |
| African / African-American | 0.0373% | 2,680 |
| Middle Eastern | 0.033% | 3,031 |
| Ashkenazi Jewish (not grpmax-eligible) | 0.00338% | 29,606 |
| Finnish (not grpmax-eligible) | 0.00156% | 64,040 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**MOGS** population constraint: LOEUF 0.85, pLI 2.6946e-10, missense-Z 0.86484. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **MOGS-congenital disorder of glycosylation** — Definitive (AR)

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 92.42, 86% of residues very-high.

## What this gene does {#gene-function}

*Describes the biological roles of MOGS (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** MOGS participates in disease-associated pathways. In Reactome, MOGS is annotated in disease pathway(s) including **Defective MOGS causes CDG-2b**, **Maturation of spike protein**.

**Disease mechanism (Reactome):** MOGS loss or alteration is curated in [Defective MOGS causes CDG-2b](https://reactome.org/content/detail/R-HSA-4793954), [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9683686), [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9694548).

### Pathways affected {#pathways}

MOGS participates in **5 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Defective MOGS causes CDG-2b](https://reactome.org/content/detail/R-HSA-4793954) | curated |
| ⚕ [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9683686) | curated |
| ⚕ [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9694548) | curated |
| [N-glycan trimming in the ER and Calnexin/Calreticulin cycle](https://reactome.org/content/detail/R-HSA-532668) | curated |
| [Regulation of CDH1 posttranslational processing and trafficking to plasma membrane](https://reactome.org/content/detail/R-HSA-9768727) | curated |

## Clinical significance {#significance}

**Conflicting classifications of pathogenicity** — review status Conflicting submitters *(criteria provided, conflicting classifications)*, last evaluated 2026-06-01.

**Submitter consensus:** conflicting (4 Likely benign, 1 Uncertain significance, 1 Benign).

**Submission history:** 6 submissions (2015–2026); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Eurofins Ntd Llc (ga) | Uncertain significance | criteria provided, single submitter | clinical testing | 2015-06-16 |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2026-01-26 |
| Blueprint Genetics | Likely benign | criteria provided, single submitter | clinical testing | 2024-11-25 |
| ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Benign | criteria provided, single submitter | clinical testing | 2024-10-30 |
| CeGaT Center for Human Genetics Tuebingen | Likely benign | criteria provided, single submitter | clinical testing | 2026-06-01 |
| GeneDx | Likely benign | criteria provided, single submitter | clinical testing | 2020-04-08 |

## Associated conditions {#conditions}

[MOGS-congenital disorder of glycosylation](https://sugi.bio/atlas/disease/mogs-congenital-disorder-of-glycosylation/).

**Reported phenotype names (ClinVar):** MOGS-congenital disorder of glycosylation, not provided, not specified, AllHighlyPenetrant, none provided, CDG 2B, CDG IIb, MOGS-CDG, GLUCOSIDASE I DEFICIENCY.

## Similar variants {#similar}

Related MOGS variant pages (same residue, condition, or type): [MOGS p.Arg495Ter](/variant/mogs-p-arg495ter), [MOGS p.Gln124Ter](/variant/mogs-p-gln124ter), [MOGS p.Gln505Ter](/variant/mogs-p-gln505ter), [MOGS p.Ala22Glu](/variant/mogs-p-ala22glu), [MOGS p.Ala292Asp](/variant/mogs-p-ala292asp), [MOGS p.Ala292Pro](/variant/mogs-p-ala292pro), [MOGS p.Ala41Val](/variant/mogs-p-ala41val), [MOGS p.Ala510Thr](/variant/mogs-p-ala510thr).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-15); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 281500). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*